Stanley Erck bagged $48M in pay as he guided Novavax on a remarkable turnaround in the hunt for a Covid-19 vaccine
Among pandemic success stories, only Moderna rivals Maryland-based Novavax’s remarkable rise from the bowels of obscurity to vaccine player. Driving that change was CEO Stanley Erck, who helped build the biotech’s supply chain from scratch — and he was paid handsomely to do it.
Erck scored a $48 million pay package in 2020, underscored by his work leading Novavax from near-bankruptcy to one of the remaining frontrunners for a Covid-19 vaccine, according to an SEC filing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.